Now Surender Surender on stage, presenting our data on CDK4/6 inhibition in experimental glioma!
@eanoassociation.bsky.social
@ghtabatabai.bsky.social
@hih-tuebingen.bsky.social
We had a wonderful #eano2025 in Prague, with multiple talks and poster presentations and fruitful discussions!
Looking forward to Rome!
@eanoassociation.bsky.social
@ghtabatabai.bsky.social
@hannes-becker1996.bsky.social
@nihalolcaydogan.bsky.social
@hih-tuebingen.bsky.social
Very happy to had the opportunity to present our data at the DGN in Berlin.
@ghtabatabai.bsky.social
@hih-tuebingen.bsky.social
@dgn-ev.bsky.social
Neurooncology Tuebingen
Neurooncology Tuebingen
Hannes Becker
Glad to have the opportunity to present our data!
@eanoassociation.bsky.social
Great talk by @ghtabatabai.bsky.social about time management in academia
@eanoassociation.bsky.social
Great comprehensive talk by @ghtabatabai.bsky.social to give insights into CRISPR screen.
More to come!
@eanoassociation.bsky.social
We are very happy to present our data at the DGN in Berlin!
@ghtabatabai.bsky.social
@hannes-becker1996.bsky.social
@dgn-ev.bsky.social
We are very happy to present you our work, recently accepted in Neurooncology!
@ghtabatabai.bsky.social @hih-tuebingen.bsky.social
academic.oup.com/neuro-oncolo...
Extremely happy that we could have contributed!
Innovative trial design, thank you for the opportunity for being part of it!
Hannes Becker
Nice opportunity to present our data on regorafenib in combination with navitoclax at @eanoassociation.bsky.social
@hannes-becker1996.bsky.social
@ghtabatabai.bsky.social
Neurooncology Tuebingen
Neurooncology Tuebingen
Neurooncology Tuebingen
AbstractBackground. Glioblastoma harbors frequent alterations in the retinoblastoma (RB1) pathway, providing a genetic rationale for therapeutic targeting
And now it‘s Hannes Becker on stage, presenting our data at EANO2025 👍🏼🙌 @neurooncotue.bsky.social
Neurooncology Tuebingen
Neurooncology Tuebingen
Neurooncology Tuebingen
Ghazaleh Tabatabai
And now it‘s Hannes Becker on stage, presenting our data at EANO2025 👍🏼🙌 @neurooncotue.bsky.social
Ghazaleh Tabatabai
🧠 The phase 1/2 N2M2 umbrella trial lead by former EANO president @wickwolfgang.bsky.social has just been published in Nature Medicine
🔗 www.nature.com/articles/s41...
#NeuroOncology #EANOessentials #BrainTumors #CancerResearch
In a phase 1/2a umbrella trial in patients with glioblastoma matching targeted therapies according to tumor molecular profiling, temsirolimus plus radiotherapy improved PFS compared to standard of car...
Excited to announce that we have completed accrual of the INTERCEPT-H3 trial (NCT04808245). This phase 1 first-in-human trial explores safety and immunogenicity of a long peptide vaccine targeting the clonal driver mutation H3K27M in adult patients with newly diagnosed diffuse midline gliomas 1/
